PE20030098A1 - SOFT ELASTIC CAPSULES AND COMPOSITIONS OF THEM - Google Patents
SOFT ELASTIC CAPSULES AND COMPOSITIONS OF THEMInfo
- Publication number
- PE20030098A1 PE20030098A1 PE2002000436A PE2002000436A PE20030098A1 PE 20030098 A1 PE20030098 A1 PE 20030098A1 PE 2002000436 A PE2002000436 A PE 2002000436A PE 2002000436 A PE2002000436 A PE 2002000436A PE 20030098 A1 PE20030098 A1 PE 20030098A1
- Authority
- PE
- Peru
- Prior art keywords
- alcohol
- amino
- filler
- initial state
- agent
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 5
- 239000008177 pharmaceutical agent Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- -1 (2-isopropyl-4-thiazolyl) -methyl Chemical group 0.000 abstract 1
- TZFSTJAMNQSGNG-UHFFFAOYSA-N 1,3-thiazol-5-ylmethyl n-(3-hydroxy-1,6-diphenylhexyl)carbamate Chemical compound C=1N=CSC=1COC(=O)NC(C=1C=CC=CC=1)CC(O)CCCC1=CC=CC=C1 TZFSTJAMNQSGNG-UHFFFAOYSA-N 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA CAPSULA COMPRENDE: I)UN RELLENO, QUE A SU VEZ CONTIENE: i)UN AGENTE O COMBINACION DE AGENTES FARMACEUTICOS, TAL COMO UN INHIBIDOR DE VIH SOLUBILIZADO QUE ES (2S,3S,5S)-5-(N-(N-((N-metil-N-N-((2-isopropil-4-tiazolil)-metil)amino)carbonil)-L-valinil)amino-2-(N-((5-tiazolil)metoxi-carbonil)-amino-1,6-difenil-3-hidroxihexano(ritonavir); ii)UN ALCOHOL; Y, iii)UN ACIDO GRASO; Y II)UN REVESTIMIENTO, QUE A SU VEZ COMPRENDE: 1)GELATINA; Y, 2)POR LO MENOS UN AGENTE PLASTIFICANTE. DONDE (II) TIENE UN ESTADO INICIAL Y UN ESTADO DE EQUILIBRIO; DE MANERA QUE EN EL ESTADO INICIAL SE SUBPLASTIFICA Y (I) CONTIENE UNA CANTIDAD EN EXCESO DE ALCOHOL RESPECTO DE LA CANTIDAD NECESARIA PARA SOLUBILIZAR EL AGENTE FARMACEUTICO Y DICHO ALCOHOL NO ESTA PRESENTE EN EL ESTADO INICIAL DE LA COMPOSICION DE REVESTIMIENTO, Y EN EL ESTADO DE EQUILIBRIO SE PLASTIFICA EL REVESTIMIENTO MEDIANTE EL ALCOHOL PROVENIENTE DEL RELLENO PARA PROPORCIONAR UNA DUREZA DE CAPSULA APROPIADA Y EL RELLENO RETIENE SUFICIENTE ALCOHOL COMO PARA MANTENER AL AGENTE FARMACEUTICO EN SOLUCIONTHE CAPSULE INCLUDES: I) A FILLER, WHICH INTO TURN CONTAINS: i) AN AGENT OR COMBINATION OF PHARMACEUTICAL AGENTS, SUCH AS A SOLUBILIZED HIV INHIBITOR WHICH IS (2S, 3S, 5S) -5- (N- (N- ((N-methyl-NN - ((2-isopropyl-4-thiazolyl) -methyl) amino) carbonyl) -L-valinyl) amino-2- (N - ((5-thiazolyl) methoxy-carbonyl) -amino- 1,6-diphenyl-3-hydroxyhexane (ritonavir); ii) AN ALCOHOL; AND, iii) A FATTY ACID; AND II) A COATING, WHICH INCLUDES: 1) GELATINE; AND, 2) AT LEAST ONE PLASTICIZING AGENT. WHERE (II) IT HAS AN INITIAL STATE AND A STATE OF EQUILIBRIUM; SO THAT IN THE INITIAL STATE IT IS UNDERPLASTIFIED AND (I) CONTAINS AN EXCESS QUANTITY OF ALCOHOL REGARDING THE AMOUNT NECESSARY TO SOLUBILIZE THE PHARMACEUTICAL AGENT AND SAID ALCOHOL IS NOT PRESENT IN THE INITIAL STATE OF THE REVERSE COMPOSITION, AND OF EQUILIBRIUM, THE COATING IS PLASTIFIED USING THE ALCOHOL FROM THE FILLER TO PROVIDE AN APPROPRIATE CAPSULE HARDNESS AND THE FILLER RETAINS ENOUGH ALCOHOL TO KEEP THE PHARMACEUTICAL AGENT IN SOLUTION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86628501A | 2001-05-25 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030098A1 true PE20030098A1 (en) | 2003-02-12 |
Family
ID=25347294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000436A PE20030098A1 (en) | 2001-05-25 | 2002-05-24 | SOFT ELASTIC CAPSULES AND COMPOSITIONS OF THEM |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1395249A1 (en) |
| JP (1) | JP2005508294A (en) |
| AR (1) | AR034995A1 (en) |
| CA (1) | CA2448438A1 (en) |
| MX (1) | MXPA03010771A (en) |
| PE (1) | PE20030098A1 (en) |
| UY (1) | UY27306A1 (en) |
| WO (1) | WO2002096395A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| KR20150021510A (en) | 2012-05-03 | 2015-03-02 | 시플라 리미티드 | Antiretroviral composition |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| GB201917252D0 (en) | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| MY121765A (en) * | 1998-07-20 | 2006-02-28 | Abbott Lab | Polymorph of ritonavir |
| SK286305B6 (en) * | 1999-06-04 | 2008-07-07 | Abbott Laboratoires | Improved pharmaceutical formulations comprising ritonavir |
| US6608198B2 (en) * | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
-
2002
- 2002-05-21 JP JP2002592907A patent/JP2005508294A/en active Pending
- 2002-05-21 EP EP02737019A patent/EP1395249A1/en not_active Withdrawn
- 2002-05-21 WO PCT/US2002/015955 patent/WO2002096395A1/en not_active Ceased
- 2002-05-21 MX MXPA03010771A patent/MXPA03010771A/en not_active Application Discontinuation
- 2002-05-21 CA CA002448438A patent/CA2448438A1/en not_active Abandoned
- 2002-05-22 AR ARP020101897A patent/AR034995A1/en not_active Application Discontinuation
- 2002-05-24 PE PE2002000436A patent/PE20030098A1/en not_active Application Discontinuation
- 2002-05-24 UY UY27306A patent/UY27306A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27306A1 (en) | 2002-12-31 |
| AR034995A1 (en) | 2004-04-14 |
| EP1395249A1 (en) | 2004-03-10 |
| CA2448438A1 (en) | 2002-12-05 |
| MXPA03010771A (en) | 2004-07-01 |
| WO2002096395A1 (en) | 2002-12-05 |
| JP2005508294A (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008003491A1 (en) | Pharmaceutical composition in solution comprising ritonavir, an organic solvent comprising a long chain fatty acid between 30-75% by total weight, water between 0.4-3.5% by total weight and optionally a surfactant (divisional of the application 1257-00). | |
| PE20100363A1 (en) | COMPOSITIONS INCLUDING NUCLEOSIDES | |
| PE20241760A1 (en) | ANTIVIRAL COMPOUNDS CONTAINING NITRILE | |
| ES2191862T3 (en) | LIQUID COMPOSITION INCLUDING AN HIV PROTEASE INHIBITOR AND A FATTY ACID OF C12-C18. | |
| MXPA06008352A (en) | A pharmaceutical composition. | |
| AR024228A1 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULIN SENSITIZER AND ANOTHER ANTI-DIABETIC AGENT | |
| UY25055A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE | |
| MX9202328A (en) | LOCAL PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT. | |
| AR027391A1 (en) | BOTULIN TOXIN PHARMACEUTICAL COMPOSITIONS | |
| ECSP045496A (en) | "INSULIN ACID PREPARATIONS WITH IMPROVED STABILITY" | |
| BR0316310A (en) | Pharmaceutical compositions having a modified vehicle | |
| AR006598A1 (en) | "ANTI-FUNGOUS COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES AND A PROCEDURE FOR THE PREPARATION" | |
| AR043863A1 (en) | COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM, USEFUL FOR INJECTION | |
| DE602004015725D1 (en) | STABILIZED LYOPHILIZED PREPARATIONS WITH TISSUE FACTOR INHIBITOR (TFPI) OR VARIATIONS OF TISSUE FACTOR INHIBITOR | |
| BR0314450A (en) | Salts of boronic acid with the addition of a pharmaceutically acceptable base, pharmaceutical formulation, and use of said salts to prepare a pharmaceutical formulation. | |
| ECSP034789A (en) | RECONSTITUABLE PARENTERAL COMPOSITION CONTAINING A COX-2 TA INHIBITOR | |
| ATE202931T1 (en) | MEDICINAL PREPARATIONS CONTAINING TAXAN DERIVATIVES | |
| BRPI0410488A (en) | hsa free stabilized liquid pharmaceutical composition, method for preparing hsa free stabilized liquid pharmaceutical composition, hermetically sealed container and kit for multiple dose administration of hsa free stabilized liquid pharmaceutical composition | |
| AR051340A1 (en) | COMPOSITE OF C (4) - ACIL PIRROLIDINE METOXIMETHYL, ITS USE TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL FORMULATION THAT UNDERSTANDS AND PROCESS TO PREPARE | |
| BR0208727A (en) | Erythropoietin improving chemotherapy-induced in vivo toxicity | |
| GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
| PE20030098A1 (en) | SOFT ELASTIC CAPSULES AND COMPOSITIONS OF THEM | |
| AR049658A2 (en) | RITONAVIR AMORFO, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION, PROCESS FOR ITS PREPARATION AND PROCESS FOR THE PREPARATION OF THE CRYSTALLINE POLYMORPHIC FORM OF RITONAVIR. | |
| BRPI0418070A (en) | personal care composition, use of a substituted urea and method for reducing color degradation of a personal care composition | |
| AR040441A1 (en) | TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |